The chief scientific officer at Satellos Bioscience discussed phase 1 findings on SAT-3247, an oral AAK1 inhibitor, highlighting its safety, pharmacokinetics, and early translatability in Duchenne muscular dystrophy. [WATCH TIME: 7 minutes]
Phil Lambert, PhD
Advertisement
Articles by Phil Lambert, PhD
The chief scientific officer at Satellos Bioscience gave clinical insight on a new novel treatment and its mechanism of action in treating Duchenne muscular dystrophy. [WATCH TIME: 5 minutes]
Advertisement
Latest Updated Articles
SAT-3247 and Restoring Muscle Regeneration in Duchenne Muscular Dystrophy: Phil Lambert, PhDPublished: March 19th 2025 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
NLRP3 Inhibitor VTX3232 Well Tolerated, Improves Parkinson Symptoms in Phase 2a Trial
2
Elecsys pTau181 Test Cleared, Tividenofusp Alfa PDUFA Pushed Back, Phase 4 LOTUS Study Highlights Real-World Benefit of Trofinetide
3
Ruptured vs Unruptured Aneurysms: Practical Decision Making with Guilherme Dabus, MD
4
Bilateral MR-Guided Focused Ultrasound Shows Benefit for Managing Parkinson Motor Complications in Phase 3 Trial
5
